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Summary. Hepatitis C virus (HCV) is one of the major causes of chronic hepatitis, cirrhosis, and hepatocellular carcinoma, 
and the development of HCV-related disease is accelerated in individuals coinfected with human immunodeficiency-1 virus 
(HIV). In the present study, we correlated different host single-nucleotide polymorphisms (SNPs) in the IL28B, CTLA4, LDLr, 
and HFE genes and mitochondrial DNA (mtDNA) haplogroups with the outcome of HCV infection and the response to 
pegylated-interferon plus ribavirin (pegIFN-RBV) treatment. Our study population consisted of 63 Majorcan patients coinfected 
with HCV and HIV and 59 anonymous unrelated controls. Whereas the population frequency of IL28B alleles was similar to 
that found in a North-American cohort of European descent, the frequency of the rs12979860 C allele was lower than that 
determined in other cohorts from Spain. The frequencies of CTLA4 and LDLr polymorphisms were comparable to those reported 
in other populations. Significant differences between cases and control cohorts occurred only for the H63D mutation of the HFE 
gene. There were no other differences in the frequencies of other polymorphisms or mtDNA haplogroups. The IL28B rs12979860 
CC genotype was shown to be associated with a rapid virological response, and the spontaneous viral clearance rate for HCV 
was higher in patients with the CTLA4+49 G allele. There was no relationship between SNPs in the LDLr and HFE genes and 
mtDNA haplogroups and the response to treatment. Our results suggest that the host genetic background plays a significant role 
in the pegIFN-RBV response of patients coinfected with HCV and HIV. [Int Microbiol 2014; 17(1):11-20]
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Introduction
 
Hepatitis C virus (HCV) is the main cause of chronic liver 
disease, including chronic hepatitis, cirrhosis, and hepatocel-
lular carcinoma [2]. The World Health Organization (WHO) 
estimates that up to 3 % of the world’s population is infected 
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with HCV, implying that there are 170–200 million carriers of 
the virus [18,33]. The prevalence of HCV infection ranges 
from less than 1 % in Northern Europe to more than 2 % on 
average in North Africa. The highest HCV prevalence (ca. 15 %) 
is in Egypt [21]. HCV transmission occurs primarily through 
transfusions of contaminated blood or blood products and in 
drug abusers through the sharing of contaminated needles and 
syringes. 
Because of the common routes of transmission, HCV-in-
fected patients are also frequently infected with the human im-
munodeficiency virus (HIV). HIV positivity has been recog-
nized as an important factor responsible for an increased mor-
bidity and mortality in HCV-infected individuals, and antiviral 
treatment for HIV modifies HCV disease outcome and surviv-
al [1,33]. Although spontaneous virus clearance (SVC) occurs 
in 15–30 % of HCV-infected adults, in 75–85 % of patients the 
infection progresses to chronic disease. Children and young 
women have a higher rate of SVC, around 45 % of the total 
number of infected individuals in these groups [32]. For many 
years, the most effective treatment for HCV infection has been 
based on the administration of interferon (IFN), which pro-
duces a sustained viral response (SVR) in 20 % of HCV-infect-
ed patients. The combination of IFN with ribavirin (RBV) and 
the subsequent addition of polyethylene glycosylated IFN 
(pegIFN) was a breakthrough in the treatment of HCV-mediat-
ed disease, increasing the response rate to 50–80 %. Patients 
who fail to show an early decline in viral load during treatment 
are less likely to achieve a SVR [3]. In addition, patient char-
acteristics such as older age, male gender, overweight, and the 
presence of cirrhosis or hepatic steatosis, insulin resistance, 
diabetes, or coinfection with HIV or hepatitis B virus (HBV) 
[3,13,27,29] are all associated with a lower rate of SVR. 
In HCV-infected patients, an important aspect of clinical 
practice is monitoring the efficacy of treatment and the dura-
tion of the effectiveness, through repeated measurements of 
HCV RNA levels. These measurements are typically per-
formed before treatment is started, at 4, 12, and 24 weeks of 
treatment and, finally, 24 weeks after the end of the treatment, 
to determine whether the patients has achieved SVR. The 
probability of achieving a SVR is inversely proportional to 
the time until the viral load becomes undetectable. Treatment 
should be discontinued at week 12 if the decrease in viral load 
is less than 2 logs (IU/ml) and at week 24 if there is still de-
tectable viral load, as in these patients the probability of a 
SVR is very low (1–3 %) [6].
Identification of the mechanisms underlying treatment 
failure in patients receiving pegIFN-RBV would be useful to 
anticipate the likelihood of their achieving a SVR. Different 
single nucleotide polymorphisms (SNPs) located upstream of 
the interleukin 28B gene (IL28B) have been related to the out-
come of HCV infection and to the success of peg-IFN-RBV 
therapy. For example, Ge et al. [9] have found a strong rela-
tion between the SNP rs12979860, located close to the IL28B 
gene, and treatment response. 
A large number of SNPs in other genes have also been 
studied for their association with disease outcome, including: 
(i) immune-related genes, such as the cytotoxic T-lymphocyte 
antigen 4 gene (CTLA4) [5,24,31,36]; (ii) lipid metabolism 
genes, such as the low density lipoprotein receptor gene 
(LDLr) [19,22,30,35]; and (iii) SNPs implicated in other liver 
diseases, such as mutations in the hereditary hemochromato-
sis gene (HFE) [4,10,16]. Other studies have used population-
related markers such as mtDNA haplogroups, which are also 
an indicator of mitochondrial function [8,14,20]. 
In this study, we examined the frequencies of the SNPs 
associated with treatment response in a cohort of HCV–HIV-
coinfected patients in Majorca. Specifically, we analyzed the 
frequencies of SNPs in the IL28B, CTLA4, LDLr, and HFE 
genes and the mtDNA haplogroups and whether either one 
correlated with the outcome of HCV infection in patients 
treated with pegIFN-RBV. At the same time, we determined 
whether the frequencies of these SNPs in our Majorcan cohort 
were similar to those in other populations.
Materials and methods
Patient and control samples. Sixty-three HCV–HIV coinfected pa-
tients were selected from those attending the Infectious Diseases Unit of Son 
Llàtzer Hospital, Palma, Balearic Islands, Spain. Inclusion criteria were posi-
tive viremia for both viruses (HCV and HIV) and seronegativity (HBsAg 
negative) for HBV. Six patients showed spontaneous HCV clearance while 
being evaluated for inclusion for HCV treatment. Spontaneous HCV clear-
ance was defined as HCV-RNA negativity but HCV seropositivity in a treat-
ment-naive patient. Fifty-seven patients were treated for 48 weeks with 
pegIFN-RBV: pegIFNα-2a: 180 µg/week or peg-IFNα-2b: 1.5 µg/kg/week 
and ribavirin according to patient weight. Patients weighing < 75 kg received 
1000 mg/day (2–0–3), and those weighing >75 kg, 1200 mg/day (3–0–3).
Buccal epithelial cells were obtained from three oral swabs and then air-
dried and stored at room temperature. DNA samples from 59 anonymous 
control individuals (29 males and 30 females) from the general Majorcan 
population were randomly selected from those available in the Genetics Lab-
oratory of the University of the Balearic Islands. The study was approved by 
the local institutional ethics committee and all patients provided informed 
consent regarding the use of their biological samples for medical research.
Variables. We constructed a database with patient variables collected ret-
rospectively by chart review. The variables consisted of the basic characteris-
tics of the patients (age, sex, body mass index, alcohol consumption). Other 
variables were biochemical markers, including aspartate transaminase (AST), 
alanine transaminase (ALT), and cholesterol, blood count (hemoglobin, leu-
kocytes, platelets), features related to infection, such as HCV genotype, HCV 
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baseline viral load, transmission route, treatment with highly active antiretro-
viral therapy (HAART), and variables related to effects of the disease. The 
latter included CD4+ T-cell count, liver damage measured by fibroscan (tran-
sient elastography) and biopsy, and the presence of hepatomegaly, spleno-
megaly, and/or hepatic steatosis. Fibrosis stage was obtained by biopsy (stage 
F0–F1) and/or fibroscan measurements (values <7.2 kPa were also consid-
ered as F0–F1 stage). Biopsy data were taken into account when both meas-
urements (biopsy and fibroscan) were available. Response to treatment was 
evaluated at 4, 12, 24, and 48 weeks (SVR). Patients were classified as having 
achieved a SVR when the viral load remained undetectable 24 weeks after the 
completion of treatment (week 48). 
Genetic polymorphisms. The SNPs IL28B rs12979860, CTLA4+49 
rs231775, CTLA4–318 rs5742909, LDLr rs14158, HFE C282Y, HFE H63D, 
and HFE S65C were evaluated, together with the mtDNA haplogroup. In the 
control samples from the Majorcan population, only the polymorphisms not 
determined in previous studies were evaluated, i.e., IL28B, CTLA4+49, 
CTLA4-318, LDLr, and HFE S65C (Table 1). Genotyping was carried out us-
ing restriction fragment length polymorphism (RFLP) techniques and, when 
necessary, DNA sequencing (for LDLr SNPs and non-H mtDNA haplogroups). 
DNA extraction and amplification. DNA was extracted from the 
oral swabs using a standard phenol-chloroform extraction method followed by 
precipitation with ethanol and NaCl. The primers designed and used in the 
present work to amplify the IL28B upstream region and the LDLr were, re-
spectively, IL28B-forward 5′-GCTTATCGCATACGGCTAGG-3′ and IL28B-
reverse 5′-AGGGACCGCTACGTAAGTCA-3′ (427 bp amplicon), and LD-
Lr-forward 5′-TGGCAGAGACAGATGGTCAG-3′ and LDLr-reverse 
5′-CACTGTCCGAAGCCTGTTCT-3′ (195 bp amplicon). The primers used 
to amplify CTLA4 (680 bp) and HFE gene (390 bp for C282Y and 208 for 
H63D/S65C) polymorphisms were those described by Nischalke et al. [24] 
and Feder et al. [7], respectively. PCRs were carried out using 40 ng of DNA, 
0.2 pM of each primer, 0.2 mM of each dNTP, and 0.75 units of Taq polymer-
ase (Dynazyme, Thermo Fisher, Lafayette, CO, USA). Amplification consist-
ed of denaturation at 94ºC for 10 min followed by 35 cycles of denaturation at 
94 ºC for 1 min, 1 min at the annealing temperature (59–60 ºC), and 1 min of 
extension at 72 ºC, with a final extension at 72 ºC for 10 min. 
The RFLP motif -7025 AluI was analyzed to determine mtDNA haplo-
group H using the following primers: 5′-CCGTAGGTGGCCTGACTGGC-3′ 
(forward) and 5′- TGATGGCAAATACAGCTCCT-3′ (reverse) [25]. PCR 
(124 bp) was carried out using 60 ng of genomic DNA, 2 pM of each primer, 
0.4 mM of each dNTP, and 1.25 units of Taq polymerase (Dynazyme). This 
PCR conditions were denaturation at 94 ºC for 5 min, followed by 35 cycles 
of denaturation at 94 ºC for 50 s, 1 min 50 s at 59 ºC (annealing), and 1 min 
of extension at 72 ºC; 5 min at 72 ºC was added at the end of the cycles. 
The mtDNA hypervariable regions of non-H samples (a 453-nucleotide 
sequence in region I and a 401-nucleotide in region II ) were analyzed using 
the primers L15996 (5′-CTCCACCATTAGCACCCAAAGC-3′) and H16401 
(5′-TGATTTCACGGAGGATGGTG-3′) for hypervariable region I, and L48 
(5′-CTCACGGGAGCTCTCCATGC-3′) and H408 (5′-CTGTTAAAAGTG-
CATACCG CCA-3′) for hypervariable region II [34]. Each PCR consisted of 
80 ng of DNA, 0.2 pM of each primer, 0.4 mM of each dNTP, and 1 unit of 
Taq polymerase (Dynazyme), with denaturation at 96 ºC for 5 min followed 
by 30 cycles of denaturation at 94 ºC for 1 min, 1 min at 50 ºC (annealing), 
and 1 min of extension at 72 ºC.
Genotyping by RFLPs. Table 2 shows the restriction enzymes, cutting 
sites, conditions used in the RFLP digestions, and the resulting band patterns. 
RFLP assays not described in the literature were designed with the tools pro-
vided on the New England Biolabs website [http://tools.neb.com/NEBcut-
ter2/]. Digested DNA was electrophoresed in EEO agarose with 1× TAE 
buffer, using ethidium bromide for DNA staining. To verify the results of the 
new RFLP assays, direct sequencing of the target SNP was performed from 
PCR amplicons. 
Genotyping by sequencing. Polymorphisms in the LDLr gene and 
the non-H mtDNA haplogroups were detected by DNA sequencing. The PCR 
products were purified using the PCRapace spin kit (Invitek, Berlin, Germa-
ny) and sequenced with the BigDye Terminator v.3.1. cycle sequencing kit 
(Applied Biosystems, Foster City, CA, USA). The samples were precipitated 
with ethanol and analyzed in an ABI 3130 automated sequencer (Applied 
Biosystems). The chromatograms and outputs were analyzed using the Bioedit 
Sequence Alignment Editor software [12]. Non-H mtDNA sequences were 
aligned and the most probable haplogroup was assigned by means of the Hap-
logrep software [haplogrep.uibk.ac.at].
Statistical methodology. The genotypic and allelic frequencies of the 
polymorphisms were calculated by direct counting. Chi-square or Fisher’s 
tests, when appropriate, were performed on contingency tables to identify 
differences in genotype distributions between cases and controls. To analyze 
associations with qualitative variables (sex, genotype virus, route of trans-
mission, biopsy data, viral load, hepatomegaly, splenomegaly, and hepatic 
steatosis), the chi-square statistic or Fisher’s test was also used on contin-
gency tables. The association of the host genotypes with a response to treat-
Table 1. Host genetic polymorphisms analyzed 
Gene Polymorphism Nucleotide change
Interleukin 28B (IL28B) rs12979860 C/T
Cytotoxic T-lymphocyte antigen 4 (CTL4) +49 (rs231775) G/A
–318 (rs5742909) C/T
Low density lipoprotein receptor (LDLr) rs14158 A/G
Hereditary hemochromatosis gene (HFE) C282Y G/A
H63D C/G
S65C T/A
Mitochondrial DNA haplogroup H
Others (non-H)
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ment (at 4, 12, and 24 weeks, SVR) or with spontaneous clarification was 
tested following the same approach.
Quantitative variables were tested for a normal distribution by the Kol-
mogorov-Smirnov test. Variables with a normal distribution were analyzed 
using Student’s t test or an ANOVA when comparing two or three groups, 
respectively. Quantitative variables that did not follow a normal distribution 
were analyzed using the nonparametric Mann-Whitney or Kruskal-Wallis 
test, for comparisons of two or three groups, respectively. All statistical cal-
culations were performed using SPSS software for Windows (Rel. 15.0.1 
2006 Chicago: SPSS Inc.).
Results
Baseline characteristics of the subjects. The 
main characteristics of the study subjects are shown in Table 3. 
Variables with a normal distribution were age, body mass in-
dex, cholesterol, hemoglobin levels, platelets, leukocytes and 
fibrosis assessed by fibroscan; quantitative variables that did 
not follow a normal distribution were AST, ALT, HCV viral 
load, and the absolute CD4 count. Gender was not evenly dis-
tributed as there were twice as many male as female patients. 
Males had higher levels of AST (P < 0.05), ALT (P < 0.05), 
and hemoglobin (P < 0.005) than females. Current injection 
drug usage was the main route of transmission, but it did not 
correlate with the degree of fibrosis. Relevant alcoholic con-
sumption (> 50 mg/day for over 2 years) was present only in 
a few female patients. In the treated patients, AST and ALT 
levels and the frequency of HCV genotype 3 infection (all 
with a P < 0.05) were higher in patients with a SVR. Six out 
of 63 patients (9.5 %) had SVC during treatment evaluation 
and were therefore not treated with pegIFN-RIB. AST and 
ALT levels were significantly lower in patients with SVC than 
in treated patients (P < 0.005). 
Frequencies of the genetic polymorphisms. All 
of the studied host genetic polymorphisms were unequivo-
cally assigned in all cases. IL28B, LDLr, CTLA4, and HFE 
(S65C) polymorphisms were analyzed in 53–58 individuals 
of the control group, depending on the SNP. The distribution 
Table 2. Conditions and band patterns in RFLP analyses
Table 2A. Conditions
Polymorphisms Enzymes Target point(polymorphic nucleotide) Temperature and time Agarose
IL28B rs12979860 Hpy166II GTN^NAC 37 oC – 3 h 2 %
CTLA4 +49 Fnu4HI GC^NGC 37 oC – 2 h 4 %
CTLA4 –318 MnlI CCTC(N)7^ 37 oC – 2 h 4 %
HFE C282Y RsaI 1 GT^AC 37 oC – 3.5 h 3 %
HFE H63D BclI 1 T^GATCA 50 oC – 2h 3 %
HFE S65C HinfI G^ANTC 37 oC – 3h 3 %
Haplogrup H AluI AG^CT 37 oC – 3h
Table 2B. Band patterns
Polymorphisms Motif bp fragment Motif bp fragment Unspecificfragment (bp)
IL28B rs12979860 C 320 T 28, 292
CTLA4 +49 A 223 G 28, 195 457
CTLA4 –318 C 59, 71 T 130 53, 111, 376
HFE C282Y Normal 250 Mutated 110, 140
HFE H63D Normal 70, 138 Mutated 208
HFE S65C Normal 58, 150 Mutated 208
Haplogrup H Haplo H 124 Non-H 80
1Ref. Lynas [17].
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Table 3. Baseline demographic, epidemiological and clinical characteristics of HCV–HIV coinfected subjects. Frequencies and proportions or means plus 
standard deviations (in parenthesis) are indicated in categorical and continuous variables, respectively.
                           Treated patients (n = 57) SVC patients (n = 6)
All patients 
(n = 63)
SVR (n = 24) no SVR (n = 31) Total 
AGE, years 42.42 (5.55) 40.77 (4.92) 41.53 (5.43) 41.67 (6.31) 42 (5)
BMI  (na = 4) 24.74 (3.01) 23.58 (3.12) 24.10 (3.10) 22.64 (3.00) 23.97 (3.09)
Cholesterol, mg/dl (na = 2) 175.70 (41.05) 174.26 (34.67) 174.57 (36.54) 212.40 (64.96) 178 (40)
AST level, U/ml (na = 1) 76.29 (45.15) 58.52 (44.04) 66.02 (44.65) P < 0.05 24.4 (8.20) 63 (44) P < 0.005
ALT level, U/ml (na = 1) 95.17 (57.79) 70.48 (56.76) 81.40 (57.56) P <0 .05 27.6 (11.31) 77 (57) P < 0.005
CD4 cell count, cell/mm3 (na = 1) 468.33 (234.21) 582.55 (339.92) 526.95 (298.35) 375.40 (148.94) 515 (291)
Haemoglobin levels, g/dl 
   (na = 11) 14.81 (1.70) 14.26 (1.48) 14.55 (1.58) 13.42 (1.66) 14.44 (1.61)
Platelet count, 109/L (na = 1) 182.71 (57.37) 208.48 (63.37) 197.18 (60.84) 242.00 (30.16) 200.79 (6.08)
Leukocytes, 103/mm3 (na = 12) 5.90 (2.16) 5.87 (1.60) 5.84 (1.81) 5.60 (1.14) 5.81 (1.75)
Gender
   (na = 2)
Male 20 19 39 2 41 (67.2)
Female 4 12 16 4 20 (32.8)
HCV viral load 
   (na = 8)
Low 8 12 20 – 20 (36.3)
High 16 19 35 – 35 (63.7)
HCV genotypes 
   (na = 9)
1 9 15 24
P < 0.05
– 24 (44.4)
3 12 5 17 – 17 (31.5)
4 2 11 13 – 13 (24.1)
Fibrosis stage
(Metavir) 
   (na = 12)
F0-F1 3 10 13 2 15 (29.4)
F2-F4 18 18 36 0 36 (70.6)
Alcohol consump.
   (na = 6)
Yes 2 1 3 0 3 (5.2)
No 16 25 41 5 46 (80.7)
Abstinent 5 3 8 0 8 (14.0)
Route of
Transmission 
   (na = 5)
IDU 21 22 43 5 48 (82.8)
Other 2 7 9 1 10 (17.2)
Highly active 
antiretroviral 
therapy (na = 2)
Yes 21 29 50 4 54 (91.5)
No 2 2 4 1 5 (8.5)
Hepatomegaly 
   (na = 8)
Yes 3 6 9 2 11(20.0)
No 20 23 43 1 44 (80.0)
Hepatic steatosis 
   (na = 20)
Yes 4 5 9 1 10 (23.3)
No 14 18 32 1 33 (76.7)
Splenomegaly 
   (na = 8)
Yes 5 8 13 1 14 (25.5)
No 18 21 39 2 41 (74.5)
Note: BMI: body mass index. AST: aspartate transaminase. ALT: alanine transaminase. Alcohol consumption: Yes: >50g for >2 years; Abstinent: no alcohol 
consumption for 6 month. HCV viral load: High: >600,000 IU/ml: Routes of transmissions: heterosexual or homosexual contact and transfusions. Fibrosis 
stage: data from biopsy and Fibroscan (F0-F1 and <7.2 kpa).na: not available data. SVR: Sustained viral response. SVC: Spontaneous viral clearance.
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of the polymorphisms is shown in Table 4. All of the polymor-
phisms were in Hardy-Weinberg equilibrium and there was no 
correlation among the variations in the SNPs. The allele dis-
tribution between patients and controls differed only for the 
H63D mutation (HFE gene), with the heterozygote genotype 
occurring more frequently in the patient cohort than in the 
controls (P = 0.002). Mitochondrial haplogroups were grouped 
into four principal groups H, J, U, and the rest of the haplo-
groups. 
Statistical analyses showed that patients with the IL28B 
rs12979860 CC genotype had lower levels of leukocytes (P = 
0.047) and platelets (P = 0.004), although for the former the 
difference was less when an outlier patient was removed from 
the analysis. In addition, HCV genotype 4 infection was less 
frequent in patients with the IL28B rs12979860 CC genotype 
(P = 0.049). The relationships were most evident when hete-
rozygous CT and homozygous TT genotypes were grouped and 
compared with the CC genotype. Moreover, ALT and AST 
transaminase levels were substantially higher in patient carriers 
of the G allele in CTLA4+49 (P = 0.021 and P = 0.063, respec-
tively) than in patients with the AA genotype. The fibroscan 
values (fibrosis) of patients carrying the CC genotype of 
CTLA4–318 were above average, although there were no dif-
ferences when fibrosis measurements by biopsy and fibroscan 
were pooled under the same variable. Spontaneous HCV 
clearance was higher in patients carrying the G allele in the 
CTLA4+49 polymorphism (P = 0.02) (Table 4 and Fig. 1B). 
For LDLr, patients with the AA genotype were more likely to 
have hepatic steatosis (P = 0.047) and a lower body mass in-
dex (P = 0.029) than those with the AG or GG genotypes. None 
Table 4. Polymorphism distribution in patients (treated versus SVC) and control cohorts
Patients
Polymorphisms Treated SVC Total Controls (%)
IL28B rs12979860 CC 19 4 23 19 (35.8)
CT 29 2 31 27 (50.9)
TT 9 0 9 7 (13.2)
CTLA4 +49 AA 29 0 29 30 (54.6)
AG 23 5 28 18 (32.7)
GG 5 1 6 7 (12.7)
CTLA4 -318 CC 49 6 55 51 (87.9)
CT 7 0 7 6 (10.4)
TT 1 0 1 1 (1.7)
HFE C282Y N 53 6 59 181 (94.3)*
Hz 4 0 4 11 (5.7)*
HFE H63D N 21 4 25 120 (62.5)*
Hz 32 2 34 69 (35.9)*
Ho 4 0 4 3 (1.6)*
HFE S65C N 55 5 60 51 (96.2)
Hz 2 1 3 2 (3.8)
LDLr GG 30 3 33 28 (51.8)
AG 21 3 24 19 (35.2)
AA 6 0 6 7 (13)
mtDNA haplogroups H 25 3 28 14 (32.6)**
J 9 1 10 4 (9.3)**
U 6 2 8 6 (14.0)**
Other 17 0 17 19 (44.2)**
*Data from Guix et al. [11]. **Data from Picornell et al. [25]. N = normals; Ho = homozygotes; Hz = heterozygotes.
Int. MIcrobIol. Vol. 17, 2014Host sNP PolymorPHisms iN HCV iNfeCtioN  17
of the patients were homozygous for the C282Y mutation in the 
HFE gene, and the prevalence of the mutation S65C was ex-
tremely low in both controls and patients. Besides the different 
prevalences of the H63D mutation in patients vs. controls, the 
most remarkable feature was that three of the four C282Y/wt 
patients, the H63D/H63D patients, and the S65C/wt patients 
had previously undergone liver biopsy, which suggests a suspi-
cion of liver involvement. Hepatomegaly was a common fea-
ture of patients belonging to the major haplogroups H, J, and U. 
Finally, ALT levels were significantly higher in patients with 
mtDNA haplogroup H and those levels were also higher, but 
not significantly, in carriers of haplogroup J.
Table 5. Distribution of the response to pegIFN-RBV treatment in males and females of the patient cohort
Male Female     Total
VR4 Negative 14 4 18 (40.9 %)
Positive 19 7 26 (59.1 %)
VR12 Negative 30 8 38 (69.1 %)
< 2 log 3 1 4 (7.3 %)
Positive 8 5 13 (23.6 %)
VR24 Negative 31 8 39 (83.0 %)
Positive 5 3 8 (17.0 %)
SVR No 19 12 31 (56.4 %)
Yes 20 4 24 (43.6 %)
SVC No 41 16 57 (90.5 %)
Yes 2 4 6 (9.5 %)
VR4, VR12, VR24: Viral load after 4, 12 and 24 weeks.
Negative: non detectable viral load; <2 log: viral load has decreased more than two log.
Positive: viral load has not significantly changed.
SVR: Sustained viral response 24 weeks after treatment. 
SVC: Spontaneous viral clearance.
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Fig. 1. (A) Grouped IL28B genotype (CC and CT_TT) and response to treatment. (B) Grouped CTLA4+49 genotype (AA and 
AG_GG) and spontaneous viral clearance (SVC). The number of patients is indicated.
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Response to pegIFN-RBV treatment. Clinical and 
virological data were obtained for treatment response at 4, 12, 
and 24 weeks, and for the SVR endpoint at 48 weeks (Table 5). 
Of the 55 patients for whom response to treatment data were 
available, 31 (56.4 %) had not achieved a SVR. As expected, 
patients infected with HCV genotype 3 had significantly high-
er SVR rates than those infected with HCV genotypes 1 and 4 
(P = 0.008). 
The relationship between treatment response and the dif-
ferent host polymorphisms is shown in Table 6. The most sig-
nificant results were obtained for the IL28B rs12979860 poly-
morphism. Patients with the CC genotype had higher SVR 
rates than those with the CT or TT genotypes (P = 0.008). The 
difference was more evident when the CC genotype was com-
pared to the pooled CT and TT genotypes (Fig. 1A). Finally, 
SVR rates were higher, but not statistically significant, in pa-
tients with the T allele in the CTLA4–318 SNP. 
Patients who did not achieve a SVR (n = 31; 56.4 %) were 
stratified in two groups. The first consisted of patients who 
never completely eliminated the virus (non-responders, n = 17; 
30.9 %); the second comprised patients with negative viral 
load at some point after starting treatment but with a later re-
bound or relapse (relapsers, n = 14; 25.5 %). An analysis of 
the relationship between the IL28B polymorphism genotype 
and relapse after treatment showed that among patients with 
the CC genotype only one had never eliminated the virus. 
Otherwise, over 50 % of the patients who had achieved a SVR 
had this genotype (CC) (P = 0.05) (Fig. 1). 
Discussion
The role of host polymorphisms in the response to 
pegIFN+RBV treatment was studied in a cohort of Majorcan 
patients with HCV–HIV coinfection. In these patients, we con-
firmed the strong relationship between the SNP rs12979860 
located upstream of the IL28B gene and the response to 
pegIFN+RBV treatment, as previously reported in HCV mo-
no-infected patients. This relationship points to the impor-
tance of this polymorphism in the evolution of HCV infection 
in HIV coinfected individuals [9]. The allele frequencies de-
tected in our cohort were similar to those of the European-
American cohort analyzed by Ge et al. [9]. However, the fre-
quency of the IL28B rs12979860 C allele was lower in our 
 
Table 6. Chi-square or Fisher tests of the response to pegIFN-RBV treatment when we analysed the differences between the genotypes 
( “/” means that the genotypes have been compared, and “–” that the genotypes are grouped)
Polymorphisms VR4 VR12 VR24 SVR SVC
IL28B rs12979860 CC / CT / TT 0.015 0.057 0.098 0.024 –
CC-CT / TT 0.076 – – – –
CC / CT-TT 0.006 0.036 0.081 0.008 –
CTLA4 +49 AA / AG / GG – – – – 0.040
AA-AG / GG – – – – –
AA / AG–GG – – – – 0.020
CTLA4 –318 CC / CT / TT – – – 0.074 –
CC-CT / TT – – – – –
CC / CT-TT – – – 0.061 –
HFE C282Y N / Hz – – – – –
HFE H63D N / Hz / Ho – – – – –
HFE S65C N / Hz – – – – –
LDLr AA / AG / GG – – – – –
AA-AG / GG – – – – –
AA / AG-GG – – – – –
mtDNA Haplogroups H / J / U / other – – – – –
Values indicated the significant probabilities. Lack of signification is indicated as “–”. The analyses were done between patients who 
have responded, or not, at 4 (VR4), 12 (VR12), 24 (VR24) weeks after starting the treatment and patients who have achieved, or not, 
spontaneous viral clearance (SVC) or sustained viral response (SVR).
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cohort than in other Spanish cohorts [23,28], despite the simi-
lar allele frequencies of our patients and the controls. Also, in 
our cohort the frequencies of other SNPs in genes related to 
the immune system, such as CTLA4 [5,24,31,36], or to lipid 
metabolism, such as LDLr [19,22,35], were similar to those 
found in other populations [19,36]. As previously noted, there 
were no differences in allele frequencies between patient cases 
and controls, nor were there differences in the mitochondrial 
haplogroups. By contrast, the H63D mutation in the HFE gene 
was the only SNP that differed in occurrence between patients 
and controls. While the reason for this difference is unknown, 
it could be related to the extremely high frequency in Spain of 
the HFE H63D mutation [11]. 
The average SVR rate of our patient cohort was similar to 
those usually reported in the literature, although the percent-
age of patients with SVC was slightly lower and, as expected, 
SVR rates were lower in patients infected with HCV geno-
types 1 and 4 than in those infected with HCV genotype 3 
[29,32].
The effect of the IL28B genotypes on SVR was significant 
and more apparent when homozygotes for the favorable 
rs12979860 CC alleles were compared with a pooled group 
comprising heterozygotes and TT homozygotes. In the entire 
cohort, only one patient with the IL28B CC genotype (infect-
ed with HCV genotype 3) did not achieve a SVR. By contrast, 
only one IL28B rs12979860 TT patient infected with geno-
type 1 or 4 virus achieved a SVR. The analyses of patients 
who had relapsed showed that the only patient classified as a 
non-responder (unable to clear HCV viral load at any time 
during treatment) had the IL28B rs12979860 CC genotype. 
Taken together, these data show that HCV–HIV coinfected 
patients with the IL28B CC genotype were able to achieve 
an induced HCV clearance with treatment, whereas in non-
responders with IL28B rs12979860 TT, treatment could not 
“rescue” the non-clearance status.
In patients infected with non-1 HCV genotypes, the role of 
IL28B polymorphisms in predicting SVR is still being inves-
tigated [29]. We found a very low frequency of the favorable 
IL28B rs12979860 CC genotype in carriers of HCV genotype 
4, known to be a difficult-to-treat viral genotype. But whether 
the virus or the unfavorable IL28B genotype precluded SVR 
in these patients remains to be established. An important find-
ing was that, irrespective of the viral genotype, the IL28B CC 
genotype promoted a rapid response to treatment, as early as 
4 weeks after treatment initiation. 
There was no relationship between polymorphisms in the 
LDLr gene and the response to treatment. Several reports 
have associated the rs14158 GG genotype with a better re-
sponse [15,26], but in our cohort this genotype was related 
only to hepatic steatosis, although these results need to be in-
terpreted with caution because of the limited sample size.
Note that all six individuals in the group with spontaneous 
HCV clearance carried the CTLA4+49 G allele. In a previous 
report, Yee et al. [36] showed that this allele improves the 
likelihood of a treatment response in patients mono-infected 
with genotype 1 HCV who were treated with non-pegylated 
IFN. However, in our cohort of HCV–HIV coinfected patients 
with HCV genotypes 1, 3, and 4, there was no significant re-
lationship between CTLA4 and the response to treatment. 
Other studies have associated the CTLA4+49 GG genotype 
with treatment response, but not with the spontaneous clear-
ance of HCV [24]. Thus, our results add further controversy to 
this issue, as there was no tendency of a better response to 
treatment in our patients with the G allele.
Finally, we found no relationship between HFE SNPs and 
any of the variables studied or the response to antiviral thera-
py. The results reported in the literature for other cohorts are 
somewhat contradictory. Note that, in our study, all H63D ho-
mozygotes, all S65C heterozygotes, and almost all C282Y 
heterozygotes had undergone liver biopsy previous to their 
inclusion in our study, which suggests at least the suspicion of 
liver damage in these patients, although this was not indicated 
in the pooled fibrosis data. 
In summary, the results of this study show the relevance of 
the CC genotype in the IL28B polymorphism regarding the 
response to pegIFN-RBV treatment in our cohort of HCV–
HIVcoinfected individuals from the Balearic Islands. While 
we identified spontaneous HCV clearance only in CTLA4+49 
G allele carriers, because of the limited sample size, this as-
sociation needs to be confirmed in other, larger cohorts.
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